Israeli Ministry Reopens Investigation Into Canadian Medical Cannabis Dumping Amid Industry Dispute
The Israeli Ministry of Economy has reopened an investigation into alleged dumping of Canadian medical cannabis imports, a probe that was previously closed due to procedural errors. The initial investigation, launched in June and closed by the end of July after the ministry failed to notify the Canadian government in advance as required by World Trade Organization rules, is now back following a corrective notification sent in early August. The investigation focuses on claims that Canadian cannabis is being imported at prices approximately 125% below local Canadian market rates, harming Israeli producers.
The renewed probe was announced by Danny Tal, the Ministry's Trade Levies Commissioner, who cited significant changes since the last attempt to impose an anti-dumping levy was blocked by Finance Minister Bezalel Smotrich in 2025. These changes include a collapse of local growers, closure of cultivation farms and production facilities, an increase in import licenses allowing companies to import without local production, and a surge in import volumes. Tal has requested all industry stakeholders to submit their positions by September 7.
The investigation stems from complaints by Israeli medical cannabis cultivators Evergreen Solomon Pharma and Trichome, who argue that the low-priced Canadian imports damage the domestic industry. The issue has sparked a fierce public and legal battle, with the Israeli Chambers of Commerce demanding the Ministry of Justice intervene to halt the investigation, calling Tal's actions "extremely unreasonable" and harmful to legal certainty and administrative finality. The Chambers have threatened legal action if the probe continues.
Meanwhile, the Israeli Cancer Association has urged Health Minister Chaim Katz to intervene, warning that renewed uncertainty and potential price increases could harm patients relying on imported medical cannabis for pain relief. The Ministry of Economy defended the investigation, emphasizing that dumping is illegal under Israeli and international law and accusing Canada of flooding the Israeli market to offload excess stock, thereby undermining local industry and patient access.
This development revives a contentious dispute that has divided Israeli government ministries and stakeholders for years, with prior opposition from the Health Ministry, the Competition Authority, and the Finance Ministry against anti-dumping levies due to concerns over market competition and patient welfare. The renewed investigation marks a critical phase in the ongoing conflict over the future of Israel's medical cannabis market and trade relations with Canada.
